Straits Times Index
3,332.80 -10.55 (-0.32%) S&P 500
5,460.48 -22.39 (-0.41%) Dow
39,118.86 -45.20 (-0.12%) Nasdaq
17,732.60 -126.08 (-0.71%) Bitcoin USD
61,573.02 +609.21 (+1.00%) CMC Crypto 200
1,279.26 -4.57 (-0.36%)
EDIT Jan 2025 17.500 call
- Insider Monkey
Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?
We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry has […]
- Insider Monkey
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?
We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other small-cap stocks. Small-cap stocks are companies with a market capitalization of somewhere between $250 million and $2 billion. They are usually […]
- Zacks
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
